Search filters

Filters
Clear All

Phase

  • 16
  • 19
  • 3
  • 1
  • 7
  • 6
  • 52
  • 5
  • 3
  • 49

Found 52 Solid Tumors trials

A listing of Solid Tumors medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Sort by:
18 years or above
All genders
Phase 1
Interventional
This study investigates the safety, tolerability, and anti-tumor activity of an investigational medication in adult patients with solid tumors that express MAGE-A4, a specific tumor-associated antigen. The study focuses on individuals with the HLA-A*02:01 tissue marker, which is necessary for participation.Participants will undergo various study procedures to evaluate the maximum …
18 years or above
All genders
Phase 1
Interventional
This study investigates the safety and effectiveness of an investigational oral medication designed to degrade SMARCA2 in patients with advanced or metastatic solid tumors that have a SMARCA4 mutation. The purpose of this study is to understand how the investigational medication affects the body, how it is processed by the …
18 years or above
All genders
Phase 1
Interventional
This study investigates the safety and effects of an investigational radioligand therapy in adults with advanced or metastatic solid tumors that have high levels of fibroblast activation protein (FAP). The study aims to understand how the investigational therapy interacts with FAP. The purpose of this study is to evaluate the …
18 years or above
All genders
Phase 1/2
Interventional
This study investigates the safety and tolerability of genetically modified autologous T cells in patients with recurrent or refractory solid tumors. The T cells are engineered to express a receptor that recognizes a specific cancer-related protein called PRAME, which is often found in melanoma and other solid tumors. The study …
18 years or above
All genders
Phase 2
Interventional
This study investigates the safety, tolerability, and preliminary effectiveness of an investigational medication, either alone or in combination with another treatment, for patients with advanced solid tumors. The study includes patients with specific types of cancer, such as urothelial cancer and non-small cell lung cancer, who have not responded to …
18 years or above
All genders
Phase 1/2
Interventional
This study investigates a treatment for patients with somatostatin receptor type 2 (SST2)-expressing neuroendocrine neoplasms (NENs) and other solid tumors. The purpose of this study is to evaluate the safety and effects of an investigational medication in individuals with these conditions.Participants in the study will receive the investigational medication to …
12 years or above
All genders
Phase 1/2
Interventional
This study investigates the safety and effectiveness of an investigational medication in patients with locally advanced or metastatic solid tumors that have a specific mutation in the TP53 gene called Y220C. The study is divided into different phases to assess the medication alone and in combination with another treatment. The …
18 years or above
All genders
Phase 1/2
Interventional
This study investigates an investigational medication designed to treat patients with advanced or metastatic solid tumors. The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of this medication both as a standalone treatment and in combination with other agents. The study is focused on …
18 years - 74 years
All genders
Phase 1
Interventional
This study investigates head and neck squamous cell carcinoma. The purpose of this study is to evaluate the safety and effectiveness of an investigational medication when used with standard chemotherapy and radiation therapy.The study focuses on assessing how well the investigational medication works with chemoradiation therapy. It evaluates the treatment's …
99 years or below
All genders
Identification of actionable genetic alterations is critical to determining the appropriate therapy in unresectable non-small cell lung cancer (NSCLC). Red blood cells (RBCs) may be an abundant and long-lasting reservoir of detectable tumor DNA. A "liquid biopsy," using blood samples from patients with advanced NSCLC to identify targetable mutations from …